Cancer Research UK logo.
SearchDonate
  • Search

A trial of targeted treatment for rare cancers that have spread (DETERMINE)

Overview

Cancer types:

All cancer types, Secondary cancers

Status:

Open

Phase:

Phase 2

Details

This trial is looking at matching targeted treatment to people who have a rare cancer. It is also looking at matching targeted treatment to people with a common cancer that has a rare gene change (mutation) in the cancer cells.

This trial is for people whose cancer has come back or got worse despite treatment. It is also for people when there is no standard treatment available for them.

The trial is for adults, teenagers and children. We use the term ‘you’, but of course if you are a parent, we are referring to your child.

Cancer Research UK supports this trial.

Recruitment start: 16 November 2022

Recruitment end: 30 November 2029

How to join

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Dr Matthew Krebs

Supported by

Cancer Research UK (Centre for Drug Development)

University of Manchester

The Royal Marsden NHS Foundation Trust

University of Birmingham

Roche

Other information

You can find out more about this trial on the DETERMINE website.

This is Cancer Research UK trial number CRUKD/21/004.

Last reviewed: 11 March 2025

CRUK internal database number: 17663

The Dangoor Education logo.

Dangoor Education

About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education

Patient Information Forum. Trusted Information Creator.
Plain English Campaign award.

Help and support

An icon of a hand shake.

Questions for your doctor

What to ask your doctor about clinical trials.

An icon of two speech bubbles, indicating a conversation.

Cancer chat forum

Meet and chat to other cancer people affected by cancer.

An icon of a landline phone.

Nurse helpline

Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.